Thus, aside the abrogation of cell cycle control by loss of CDKN2A/B, damaging mutations in BTG1 may provide a survival advantage to CLL cells under targeted BCL2-inhibition. This evidence concerns the gene BTG1 and B-cell chronic lymphocytic leukemia.